Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk…

PSMA PET/CT improves outcomes for men with recurrent prostate cancer

A new study from Denmark shows for the first time that men with biochemically recurrent prostate…